Suven Life Sciences secured product patent from Japanese Patent Office (JPO) for one of their New Chemical Entity (NCE) to treat disorders of the central nervous system (Neurodegenerative diseases).
The granted claims of the patent include the class of selective Serotonin receptor affinity compounds discovered by the company and are being developed as therapeutic agents. According to the invention, the compounds are useful in the treatment of cognitive impairment associated with Alzheimer's disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington's Disease, Parkinson's and Schizophrenia.
Suven Life's several product patent applications are in the pipeline. Products out of these inventions may be out-licensed at the stage of clinical Phase-I or Phase-II. Venkat Jasti, chief executive officer, Suven Life Sciences said, "Our pipeline of molecules in the central nervous system arena that are being developed for cognitive disorders has an estimated market potential of $20 billion globally."
This is Suven Life's first product patent granted in Japan and is valid till 2023.